Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compumedics Limited ( (AU:CMP) ) has shared an update.
Compumedics Limited has appointed Christopher R. Barys, a seasoned MedTech executive, as a Non-Executive Director to enhance its U.S. growth and capital market strategy. This strategic move aims to leverage Barys’ extensive experience and networks to address the company’s valuation gap compared to global peers and accelerate the commercialization of its Somfit® and OrionMEG® products. The company reported a 22% year-on-year increase in sales orders and anticipates further growth with a projected revenue exceeding $70 million in FY26. The strengthened board will focus on strategic partnerships and investor relations to unlock Compumedics’ potential in the U.S. market.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is a global medical device company specializing in diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. Founded in 1987, the company has expanded its international reach through subsidiaries like Neuroscan in the US and DWL Elektronishe GmbH in Germany, serving markets across the Americas, Australia, Asia Pacific, Europe, and the Middle East. Compumedics is recognized for its innovation and has received numerous awards, including Australia’s Exporter of the Year.
Average Trading Volume: 113,324
Technical Sentiment Signal: Sell
Current Market Cap: A$54.78M
For an in-depth examination of CMP stock, go to TipRanks’ Overview page.